

Daftar Pustaka

- Al, M.H.E.T., Humbert, M., Kovacs, G., Hoeper, M.M., *et al.*, 2022. 2022 ESC / ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.
- Anderson, J.J., Lau, E.M., Lavender, M., Benza, R., *et al.*, 2020. Retrospective Validation of the REVEAL 2.0 Risk Score With the Australian and New Zealand Pulmonary Hypertension Registry Cohort. *Chest* 157: 162–172. doi:10.1016/j.chest.2019.08.2203
- Barst, R.J., McGoon, M., McLaughlin, V., Tapson, V., *et al.*, 2003. Beraprost therapy for pulmonary arterial hypertension. *J. Am. Coll. Cardiol.* 41: 2119–2125. doi:10.1016/S0735-1097(03)00463-7
- Baumgartner, H., De Backer, J., Babu-Narayan, S. V., Budts, W., *et al.*, 2021. 2020 ESC Guidelines for the management of adult congenital heart disease. *Eur. Heart J.* 42: 563–645. doi:10.1093/eurheartj/ehaa554
- Benza, R.L., Kanwar, M.K., Raina, A., Scott, J. V., *et al.*, 2021. Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension. *Chest* 159: 337–346. doi:10.1016/j.chest.2020.08.2069
- Boucly, A., Weatherald, J., Savale, L., de Groote, P., *et al.*, 2022. External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry. *Eur. Respir. J.* 59. doi:10.1183/13993003.02419-2021
- Boucly, A., Weatherald, J., Savale, L., Jaïs, X., *et al.*, 2017. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. *Eur. Respir. J.* 50: 1–10. doi:10.1183/13993003.00889-2017
- Brida, M., Nashat, H., & Gatzoulis, M.A., 2020. Pulmonary arterial hypertension: closing the gap in congenital heart disease. *Curr. Opin. Pulm. Med.* 26: 422–428. doi:10.1097/MCP.0000000000000695
- Corris, P.A., 2020. Risk stratification in PAH. *Glob. Cardiol. Sci. Pract.* 2020. doi:10.21542/GCSP.2020.9
- Dadlani, G.H., Sosa, P., Cobb, H., & Akshatha, A., 2016. Pediatric pulmonary hypertension: Diagnosis and management. *Curr. Opin. Cardiol.* 31: 78–87. doi:10.1097/HCO.0000000000000243
- Dahlan, M.S., 2016. Besar Sampel untuk Penelitian Kedokteran dan Kesehatan, 4th ed. Jakarta: Epidemiologi Indonesia.
- Delcroix, M., & Howard, L., 2015. Pulmonary arterial hypertension: The burden of disease and impact on quality of life. *Eur. Respir. Rev.* 24: 621–629. doi:10.1183/16000617.0063-2015
- Dinarti, L.K., Anggrahini, D.W., Lilyasari, O., Siswanto, B.B., *et al.*, 2021. Pulmonary arterial hypertension in Indonesia: Current status and local application of international guidelines. *Glob. Heart* 16: 1–11. doi:10.5334/GH.944
- Dinarti, L.K., Hartopo, A.B., Kusuma, A.D., Satwiko, M.G., *et al.*, 2020. The COngenital HeARt Disease in adult and Pulmonary Hypertension (COHARD-PH) registry: A descriptive study from single-center hospital registry of adult congenital heart disease and pulmonary hypertension in Indonesia. *BMC Cardiovasc. Disord.* 20: 1–11.

doi:10.1186/s12872-020-01434-z

- Emmons-Bell, S., Johnson, C., Boon-Dooley, A., Corris, P.A., *et al.*, 2022. Prevalence, incidence, and survival of pulmonary arterial hypertension: A systematic review for the global burden of disease 2020 study. *Pulm. Circ.* 12: 1–15. doi:10.1002/pul2.12020
- Frantz, R.P., McDevitt, S., & Walker, S., 2012. Baseline NT-proBNP correlates with change in 6-minute walk distance in patients with pulmonary arterial hypertension in the pivotal inhaled treprostinil study TRIUMPH-1. *J. Hear. Lung Transplant.* 31: 811–816. doi:10.1016/j.healun.2012.04.005
- Galiè, N., Humbert, M., Vachiery, J.L., Gibbs, S., *et al.*, 2015. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. *Eur. Respir. J.* 46: 903–975. doi:10.1183/13993003.01032-2015
- Galiè, N., Seeger, W., Naeije, R., Simonneau, G., *et al.*, 2004. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. *J. Am. Coll. Cardiol.* 43: S81–S88. doi:10.1016/j.jacc.2004.02.038
- Gan, C.T., McCann, G.P., Marcus, J.T., van Wolferen, S.A., *et al.*, 2006. NT-proBNP reflects right ventricular structure and function in pulmonary hypertension. *Eur. Respir. J.* 28: 1190–1194. doi:10.1183/09031936.00016006
- Ghofrani, H.-A., Galiè, N., Grimminger, F., Grünig, E., *et al.*, 2013. Riociguat for the Treatment of Pulmonary Arterial Hypertension. *N. Engl. J. Med.* 369: 330–340. doi:10.1056/nejmoa1209655
- Goldstein, S.A., & Krasuski, R.A., 2022. Pulmonary Hypertension in Adults with Congenital Heart Disease. *Cardiol. Clin.* 40: 55–67. doi:10.1016/j.ccl.2021.08.006
- Hoepfer, M.M., Pausch, C., Olsson, K.M., Huscher, D., *et al.*, 2022. COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension. *Eur. Respir. J.* 60: 1–12. doi:10.1183/13993003.02311-2021
- Hoepfer, M.M., Pittrow, D., Opitz, C., Gibbs, J.S.R., *et al.*, 2018. Risk assessment in pulmonary arterial hypertension. *Eur. Respir. J.* 51. doi:10.1183/13993003.02606-2017
- Humbert, M., Germany, M.M.H., Berger, R.M.F., Denmark, J.C., *et al.*, 2022. 2022 ESC / ERS Guidelines for the diagnosis and treatment of pulmonary hypertension Developed by the task force for the diagnosis and treatment of (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lu. *Eur. Heart J.* 1–114.
- Kylhammar, D., Kjellström, B., Hjalmarsson, C., Jansson, K., *et al.*, 2018. A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. *Eur. Heart J.* 39: 4175–4181. doi:10.1093/eurheartj/ehx257
- Leber, L., Beaudet, A., & Muller, A., 2021. Epidemiology of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: identification of the most accurate estimates from a systematic literature review. *Pulm. Circ.* 11. doi:10.1177/2045894020977300
- Naeije, R., & Manes, A., 2014. The right ventricle in pulmonary arterial hypertension. *Eur. Respir. Rev.* 23: 476–487. doi:10.1183/09059180.00007414
- Olsson, K.M., Delcroix, M., Ghofrani, H.A., Tiede, H., *et al.*, 2014. Anticoagulation and survival in pulmonary arterial hypertension: Results from the comparative, prospective registry of newly initiated therapies for pulmonary hypertension (COMPERA). *Circulation* 129: 57–65. doi:10.1161/CIRCULATIONAHA.113.004526



- Souza, R., Jardim, C., Julio Cesar Fernandes, C., Silveira Lapa, M., *et al.*, 2007. NT-proBNP as a tool to stratify disease severity in pulmonary arterial hypertension. *Respir. Med.* 101: 69–75. doi:10.1016/j.rmed.2006.04.014
- Vraka, A., Yerly, P., & Aubert, J.D., 2022. Comparison of Risk Stratification Scores in Pulmonary Arterial Hypertension: A Monocentric Retrospective Study at Lausanne University Hospital. *Respiration* 101: 565–576. doi:10.1159/000520886
- Wang, K.Y., 2017. The changing landscape of pulmonary arterial hypertension in 21st century. *Acta Cardiol. Sin.* 33: 510–513. doi:10.6515/ACS20170810A